vs
GREAT SOUTHERN BANCORP, INC.（GSBC）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
GREAT SOUTHERN BANCORP, INC.的季度营收约是REGENXBIO Inc.的1.9倍（$56.4M vs $30.3M），GREAT SOUTHERN BANCORP, INC.净利率更高（28.9% vs -221.3%，领先250.2%），REGENXBIO Inc.同比增速更快（43.0% vs -0.2%），GREAT SOUTHERN BANCORP, INC.自由现金流更多（$70.1M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 4.5%）
该企业是美国的多元化银行金融机构，总部位于明尼苏达州明尼阿波利斯，在特拉华州注册。截至2025年，它是美国第五大银行，也是美国中西部规模最大的银行，被金融稳定委员会认定为具有系统重要性的金融机构，主营零售及企业银行业务、投资、抵押贷款等多元金融服务。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
GSBC vs RGNX — 直观对比
营收规模更大
GSBC
是对方的1.9倍
$30.3M
营收增速更快
RGNX
高出43.2%
-0.2%
净利率更高
GSBC
高出250.2%
-221.3%
自由现金流更多
GSBC
多$122.9M
$-52.8M
两年增速更快
RGNX
近两年复合增速
4.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $56.4M | $30.3M |
| 净利润 | $16.3M | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | 34.5% | -190.0% |
| 净利率 | 28.9% | -221.3% |
| 营收同比 | -0.2% | 43.0% |
| 净利润同比 | 9.1% | -31.2% |
| 每股收益（稀释后） | $1.44 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GSBCRGNX
| Q4 25 | $56.4M | $30.3M | ||
| Q3 25 | $57.8M | $29.7M | ||
| Q2 25 | $59.2M | $21.4M | ||
| Q1 25 | $55.9M | $89.0M | ||
| Q4 24 | $56.5M | $21.2M | ||
| Q3 24 | $55.0M | $24.2M | ||
| Q2 24 | $56.7M | $22.3M | ||
| Q1 24 | $51.6M | $15.6M |
净利润GSBCRGNX
| Q4 25 | $16.3M | $-67.1M | ||
| Q3 25 | $17.8M | $-61.9M | ||
| Q2 25 | $19.8M | $-70.9M | ||
| Q1 25 | $17.2M | $6.1M | ||
| Q4 24 | $14.9M | $-51.2M | ||
| Q3 24 | $16.5M | $-59.6M | ||
| Q2 24 | $17.0M | $-53.0M | ||
| Q1 24 | $13.4M | $-63.3M |
毛利率GSBCRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率GSBCRGNX
| Q4 25 | 34.5% | -190.0% | ||
| Q3 25 | 38.2% | -176.3% | ||
| Q2 25 | 41.0% | -296.3% | ||
| Q1 25 | 38.4% | 13.6% | ||
| Q4 24 | 31.8% | -242.1% | ||
| Q3 24 | 36.6% | -256.6% | ||
| Q2 24 | 36.8% | -251.3% | ||
| Q1 24 | 32.1% | -408.8% |
净利率GSBCRGNX
| Q4 25 | 28.9% | -221.3% | ||
| Q3 25 | 30.7% | -208.3% | ||
| Q2 25 | 33.4% | -331.8% | ||
| Q1 25 | 30.7% | 6.8% | ||
| Q4 24 | 26.4% | -241.3% | ||
| Q3 24 | 30.0% | -246.3% | ||
| Q2 24 | 30.0% | -237.7% | ||
| Q1 24 | 26.0% | -405.4% |
每股收益（稀释后）GSBCRGNX
| Q4 25 | $1.44 | $-1.30 | ||
| Q3 25 | $1.56 | $-1.20 | ||
| Q2 25 | $1.72 | $-1.38 | ||
| Q1 25 | $1.47 | $0.12 | ||
| Q4 24 | $1.27 | $-0.99 | ||
| Q3 24 | $1.41 | $-1.17 | ||
| Q2 24 | $1.45 | $-1.05 | ||
| Q1 24 | $1.13 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $189.6M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $636.1M | $102.7M |
| 总资产 | $5.6B | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资GSBCRGNX
| Q4 25 | $189.6M | $230.1M | ||
| Q3 25 | $196.2M | $274.2M | ||
| Q2 25 | $245.9M | $323.3M | ||
| Q1 25 | $217.2M | $267.9M | ||
| Q4 24 | $195.8M | $234.7M | ||
| Q3 24 | $208.4M | $255.5M | ||
| Q2 24 | $186.5M | $290.4M | ||
| Q1 24 | $171.4M | $338.7M |
股东权益GSBCRGNX
| Q4 25 | $636.1M | $102.7M | ||
| Q3 25 | $632.9M | $161.5M | ||
| Q2 25 | $622.4M | $213.7M | ||
| Q1 25 | $613.3M | $274.2M | ||
| Q4 24 | $599.6M | $259.7M | ||
| Q3 24 | $612.1M | $301.4M | ||
| Q2 24 | $568.8M | $348.3M | ||
| Q1 24 | $565.2M | $390.7M |
总资产GSBCRGNX
| Q4 25 | $5.6B | $453.0M | ||
| Q3 25 | $5.7B | $525.2M | ||
| Q2 25 | $5.9B | $581.0M | ||
| Q1 25 | $6.0B | $490.9M | ||
| Q4 24 | $6.0B | $466.0M | ||
| Q3 24 | $6.0B | $519.1M | ||
| Q2 24 | $6.0B | $569.4M | ||
| Q1 24 | $5.8B | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $81.5M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $70.1M | $-52.8M |
| 自由现金流率自由现金流/营收 | 124.3% | -174.0% |
| 资本支出强度资本支出/营收 | 20.3% | 1.7% |
| 现金转化率经营现金流/净利润 | 5.01× | — |
| 过去12个月自由现金流最近4个季度 | $121.9M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流GSBCRGNX
| Q4 25 | $81.5M | $-52.3M | ||
| Q3 25 | $5.6M | $-56.0M | ||
| Q2 25 | $39.3M | $-49.3M | ||
| Q1 25 | $15.0M | $33.6M | ||
| Q4 24 | $44.1M | $-31.6M | ||
| Q3 24 | $17.7M | $-40.5M | ||
| Q2 24 | $43.5M | $-45.5M | ||
| Q1 24 | $-26.9M | $-55.5M |
自由现金流GSBCRGNX
| Q4 25 | $70.1M | $-52.8M | ||
| Q3 25 | $3.9M | $-56.5M | ||
| Q2 25 | $34.9M | $-49.7M | ||
| Q1 25 | $13.1M | $32.6M | ||
| Q4 24 | $39.1M | $-32.7M | ||
| Q3 24 | $16.5M | $-40.9M | ||
| Q2 24 | $42.0M | $-46.0M | ||
| Q1 24 | $-27.7M | $-56.0M |
自由现金流率GSBCRGNX
| Q4 25 | 124.3% | -174.0% | ||
| Q3 25 | 6.7% | -189.9% | ||
| Q2 25 | 59.0% | -232.8% | ||
| Q1 25 | 23.4% | 36.6% | ||
| Q4 24 | 69.3% | -154.2% | ||
| Q3 24 | 30.1% | -168.9% | ||
| Q2 24 | 74.1% | -206.2% | ||
| Q1 24 | -53.7% | -358.5% |
资本支出强度GSBCRGNX
| Q4 25 | 20.3% | 1.7% | ||
| Q3 25 | 3.0% | 1.7% | ||
| Q2 25 | 7.4% | 1.8% | ||
| Q1 25 | 3.5% | 1.2% | ||
| Q4 24 | 8.7% | 5.1% | ||
| Q3 24 | 2.1% | 1.3% | ||
| Q2 24 | 2.7% | 2.1% | ||
| Q1 24 | 1.6% | 3.6% |
现金转化率GSBCRGNX
| Q4 25 | 5.01× | — | ||
| Q3 25 | 0.31× | — | ||
| Q2 25 | 1.99× | — | ||
| Q1 25 | 0.87× | 5.53× | ||
| Q4 24 | 2.95× | — | ||
| Q3 24 | 1.07× | — | ||
| Q2 24 | 2.56× | — | ||
| Q1 24 | -2.01× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GSBC
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
